Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response

Background: Few studies have provided real-world evidence of mepolizumab efficacy and safety. We aimed to evaluate mepolizumab for severe eosinophilic asthma in daily clinical practice. Research design and methods: Patients included in the RINOVA (Interdisciplinary Network for the management of seve...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Expert review of respiratory medicine Jg. 13; H. 12; S. 1205 - 1212
Hauptverfasser: Caminati, Marco, Cegolon, Luca, Vianello, Andrea, Chieco Bianchi, Fulvia, Festi, Giuliana, Marchi, Maria R, Micheletto, Claudio, Mazza, Francesco, Tognella, Silvia, Senna, Gianenrico
Format: Journal Article
Sprache:Englisch
Veröffentlicht: England Taylor & Francis 02.12.2019
Schlagworte:
asthma network
eosinophils
mepolizumab
real-world evidence
Severe asthma
eosinophils
real-world evidence
Severe asthma
mepolizumab
asthma network
ISSN:1747-6348, 1747-6356, 1747-6356
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background: Few studies have provided real-world evidence of mepolizumab efficacy and safety. We aimed to evaluate mepolizumab for severe eosinophilic asthma in daily clinical practice. Research design and methods: Patients included in the RINOVA (Interdisciplinary Network for the management of severe asthma in Veneto region, Italy) database were investigated. Blood eosinophil count, forced expiratory volume in 1 second, % of predicted (FEV1%), fractional exhaled nitric oxide (FeNO), asthma control test (ACT), oral steroid (OCS) intake, and exacerbation rate were evaluated during mepolizumab treatment. Results: 69 patients were enrolled (mean age: 55.1 years; 60.9% females). A significant improvement was detected at one month with respect to blood eosinophils (median level at baseline: 710/μl; −620/μl, p < 0,001), FEV1% (median value at baseline 87; range: 79-101; +4, p = 0.001) and ACT (median value at baseline 18; range: 14-20.5;+4, <0.001). A significant reduction of FeNO was observed six months after the treatment start, when the exacerbation rate and the mean OCS dose significantly decreased (respectively: Δ reduction −3; p < 0.001 and −5 mg; p < 0.001). Conclusions: Our study provides real-world evidence of mepolizumab safety and confirms its dramatic steroid sparing effect. The greatest clinical change (ACT and FEV1) was observed within the first month.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1747-6348
1747-6356
1747-6356
DOI:10.1080/17476348.2019.1676734